Endo International PLC banner
E

Endo International PLC
LSE:0Y5F

Watchlist Manager
Endo International PLC
LSE:0Y5F
Watchlist
Price: 926.8 USD -0.1% Market Closed
Market Cap: $207.9B

Relative Value

There is not enough data to reliably calculate the relative value of 0Y5F.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

0Y5F Relative Value
Base Case
Not Available
E
Worst Case
Base Case
Best Case

Multiples Across Competitors

0Y5F Competitors Multiples
Endo International PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
US
Eli Lilly and Co
NYSE:LLY
964.1B USD 14.8 46.6 31.4 33.4
US
Johnson & Johnson
NYSE:JNJ
586.6B USD 6.2 21.9 15.2 18.7
CH
Roche Holding AG
SIX:ROG
295B CHF 4.8 31.4 13.2 15.4
UK
AstraZeneca PLC
LSE:AZN
242.6B GBP 5.6 32.3 17.8 25.1
CH
Novartis AG
SIX:NOVN
248.1B CHF 5.7 22.8 14 18
US
Merck & Co Inc
NYSE:MRK
300.1B USD 4.6 16.4 10.3 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.4 9.8 11.5
US
Pfizer Inc
NYSE:PFE
155.8B USD 2.5 20.1 7.5 10
UK
GlaxoSmithKline PLC
LSE:GSK
92.5B GBP 2.8 16.2 8.1 11.5
UK
GSK plc
XETRA:GS71
105.8B EUR 2.8 16.1 8.1 11.5
P/E Multiple
Earnings Growth PEG
IE
E
Endo International PLC
LSE:0Y5F
Average P/E: 23.7
Negative Multiple: -74.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.6
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
21.9
7%
3.1
CH
Roche Holding AG
SIX:ROG
31.4
29%
1.1
UK
AstraZeneca PLC
LSE:AZN
32.3
26%
1.2
CH
Novartis AG
SIX:NOVN
22.8
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.4
14%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
13.4
7%
1.9
US
Pfizer Inc
NYSE:PFE
20.1
26%
0.8
UK
GlaxoSmithKline PLC
LSE:GSK
16.2
18%
0.9
UK
GSK plc
XETRA:GS71
16.1
18%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
E
Endo International PLC
LSE:0Y5F
Average EV/EBITDA: 42.6
333.1
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.4
18%
1.7
US
Johnson & Johnson
NYSE:JNJ
15.2
2%
7.6
CH
Roche Holding AG
SIX:ROG
13.2
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
17.8
11%
1.6
CH
Novartis AG
SIX:NOVN
14
9%
1.6
US
Merck & Co Inc
NYSE:MRK
10.3
7%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
7%
1.4
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
8.1
2%
4.1
UK
GSK plc
XETRA:GS71
8.1
2%
4.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
E
Endo International PLC
LSE:0Y5F
Average EV/EBIT: 91.1
835.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.4
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.7
6%
3.1
CH
Roche Holding AG
SIX:ROG
15.4
6%
2.6
UK
AstraZeneca PLC
LSE:AZN
25.1
24%
1
CH
Novartis AG
SIX:NOVN
18
12%
1.5
US
Merck & Co Inc
NYSE:MRK
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
8%
1.4
US
Pfizer Inc
NYSE:PFE
10
-1%
N/A
UK
GlaxoSmithKline PLC
LSE:GSK
11.5
12%
1
UK
GSK plc
XETRA:GS71
11.5
12%
1